NEOsphere Biotechnologies offers an end‑to‑end platform that combines industrial‑scale data‑independent acquisition mass spectrometry with fully automated biostatistical pipelines to generate large‑scale degrader target portfolios for targeted protein degradation programs. Their service screens compounds against more than 11,000 proteins and captures up to 50,000 ubiquitination sites per sample, delivering high‑throughput, reproducible proteomic data that can be directly integrated into drug discovery workflows.
Funding
$6.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Pharmaceutical researchers lack scalable, high‑throughput proteomics methods to identify and validate novel targets for targeted protein degradation (TPD), making it difficult to assess compound‑induced ubiquitination and proteome‑wide effects across large libraries of degrader candidates.
Solution
NEOsphere Biotechnologies provides an end‑to‑end platform that combines industrial‑scale data‑independent acquisition mass spectrometry (DIA‑MS) with fully automated biostatistical pipelines to generate comprehensive degrader target portfolios. Their Deep Proteomic Screening service evaluates compounds against more than 11,000 proteins, enabling rapid assessment of selectivity, potency, and efficacy during drug optimization cycles. Complementary global ubiquitinomics captures up to 50,000 ubiquitination sites per sample, delivering detailed insight into compound‑induced ubiquitination without proteasome inhibition or genetic manipulation. The platform delivers high reproducibility, sensitivity, and speed through automated quality control, normalization, batch correction, and differential abundance testing, turning raw proteomics data into actionable biological knowledge for TPD programs.
Target Audience
Primary customers are pharmaceutical and biotech companies developing targeted protein degradation therapeutics, as well as academic research groups conducting large‑scale proteomics‑driven target discovery and validation.
Features
- Single‑shot DIA‑MS workflow with automated sample processing for both adherent, suspension, and primary cells or tissues
- Proprietary biostatistical pipeline (DIA‑NN, custom normalization, batch correction, refined linear models) ensuring high precision and reproducibility
- Coverage of >11,000 proteins in degrader screens and up to 50,000 ubiquitination sites per sample for deep ubiquitinomics
- High‑throughput capacity to screen tens of thousands of degrader compounds with rapid turnaround
- Sensitive detection of low‑abundance proteins and subtle protein changes across the proteome
- Integrated data security and cloud‑ready output for seamless transfer into drug discovery pipelines